Global Kinetics Corporation’s PKG® Smartwatch Provides Clinically Meaningful Improvement in Parkinson’s Disease Symptom Assessment, Management and Medication Optimization, As Well As Projected Per Patient Cost Savings
November 02, 2018 09:00 ET
|
Global Kinetics Corporation
Data Recently Presented at the 2018 International Congress of Parkinson’s Disease and Movement Disorders PORTSMOUTH, N.H., LONDON and MELBOURNE, Australia, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Global...
Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
June 22, 2018 09:12 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...
Adamas Announces Publication of Amantadine Immediate Release Subgroup Analysis From EASE LID 2 Open-label Study in Movement Disorders Clinical Practice
February 08, 2018 09:00 ET
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that subgroup analyses of Parkinson’s disease patients taking amantadine immediate...